Physician profile
Kathy Hwang
NPI 1548263817
$2,784.61
in general payments reported to CMS, 2019-2025
16 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $172 · 2021: $211 · 2022: $428 · 2023: $633 · 2024: $713 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $395.13 | 2022-2024 | Vabysmo |
| Biotissue Holdings INC. | $377.72 | 2024-2025 | |
| Allergan, INC. | $260.65 | 2019-2022 | |
| Alcon Vision LLC | $259.97 | 2021-2024 | Hydrus Microstent, Rocklatan, Eysuvis |
| Aerie Pharmaceuticals, INC. | $247.55 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $232.69 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $224.68 | 2023-2024 | Syfovre |
| Mallinckrodt Hospital Products INC. | $143.92 | 2023 | Acthar |
| Dompe US, INC. | $141.85 | 2019-2025 | Oxervate |
| Sight Sciences, INC. | $127.15 | 2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Genentech, INC. | $121.74 | 2025 | Vabysmo |
| Oyster Point Pharma, INC. | $53.72 | 2023 | Tyrvaya |
| Thea Pharma INC. | $42.30 | 2023-2024 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $17.96 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.